Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Febrile Neutropenia Market from 2024 to 2025?
The market size of febrile neutropenia has seen robust growth in the past few years. There is an expected rise from $10.60 billion in 2024 to $11.31 billion in 2025, projecting a compound annual growth rate (CAGR) of 6.7%. This growth during the historical period is due to several factors such as an increase in cancer cases, the widespread use of chemotherapy, the proliferation of personalized medicine, a decrease in healthcare expenses, and a rise in instances of neutropenia.
What Is the Projected Market Size of the Febrile Neutropenia Market?
The market size for febrile neutropenia is projected to experience significant expansion in the coming years. An expected growth of up to $14.48 billion is forecasted by 2029, marking a compound annual growth rate (CAGR) of 6.4%. The anticipated growth during this prediction period is a result of factors such as the increased usage of immunosuppressive drugs, intensifying research and development, positive reimbursement policies, elevated investment levels, and a heightened number of leukemia cases. The forecast period also indicates key trends, including quick molecular diagnostics, the application of antimicrobial stewardship and de-escalation therapy, the use of immunotherapy & targeted treatments, risk stratification models, and progress in fungal biomarkers.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp
Who are the Major Competitors in the Febrile Neutropenia Market Outlook?
Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech
What Is Fueling Growth in the Febrile Neutropenia Market?
Progress in the febrile neutropenia market is anticipated to be spurred on by the rising incidence of cancer. Cancer is a multifaceted set of diseases, identifiable by unregulated cell growth that can invade local tissues and metastasize. The escalating prevalence of cancer can be attributed to factors such as the aging demographic, environmental and occupational risk exposures, genetic tendencies, as well as hormonal and reproductive factors. Febrile neutropenia aids cancer patients by underscoring the increased risk of infections during chemotherapy. This facilitates prompt interventions and specialized treatment to avert critical complications, thus improving patient prognosis and enabling cancer treatments to continue without delay. For instance, the American Cancer Society, a non-profit cancer awareness organization in the US, reported in January 2022, that the country is expected to register approximately 1.9 million new cancer cases and 609,360 cancer-related fatalities, averaging around 1,670 deaths daily. As a result, the growing prevalence of cancer is fueling the expansion of the febrile neutropenia market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21187&type=smp
Which Febrile Neutropenia Market Segments Are Growing the Fastest?
The febrile neutropenia market covered in this report is segmented –
1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care
2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders
3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections
4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration
Subsegments:
1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems
2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy
3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management
Which Industry Trends Are Shaping the Future of the Febrile Neutropenia Market?
Large corporations within the febrile neutropenia sector are directing their efforts towards the creation of state-of-the-art biosimilar drugs, aimed at improving the availability of treatments. Biosimilars are biologic medications that are created to replicate the approved reference drugs in terms of their structure, function, and effectiveness. As lower-cost options to the original biologics, these drugs enhance patient access while also meeting stringent regulatory requirements. For example, in September 2022, the U.S. FDA approved the biosimilar Stimufend (pegfilgrastim-fpgk), developed by Fresenius Kabi, a pharmaceutical firm based in Germany. This approval greenlights the use of Stimufend for patients suffering from non-myeloid malignant conditions who are undergoing myelosuppressive chemotherapy, a possible cause of febrile neutropenia, a severe condition marked by an abnormally low count of white blood cells and fever. By early 2023, Fresenius Kabi plans to introduce Stimufend in a prefilled syringe form, with plans for an on-body injector currently in the pipeline.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report
Which Countries Are Leading the Febrile Neutropenia Market?
North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21187
This Report Delivers Insight On:
1. How big is the febrile neutropenia market, and how is it changing globally?
2. Who are the major companies in the febrile neutropenia market, and how are they performing?
3. What are the key opportunities and risks in the febrile neutropenia market right now?
4. Which products or customer segments are growing the most in the febrile neutropenia market?
5. What factors are helping or slowing down the growth of the febrile neutropenia market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model